NICE revises its decision on dapagliflozin in triple therapy

NICE has published new guidance recommending the use of dapagliflozin (Forxiga) as an option for treating type II diabetes in adults as part of a triple therapy regimen with metformin and a sulfonylurea.

This supercedes earlier guidance, published in June 2013 (Technology Appraisal Guidance TA288, recommendation 1.3), in which NICE recommended that the use of dapagliflozin as triple therapy with metformin and a sulfonylurea should be confined to clinical trials.

Dapagliflozin is available as Forxiga and as a combined tablet containing both dapagliflozin and metformin (Xigduo).


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.